Trial reportAmerican journal of respiratory and critical care medicine2009
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.
Trial report in American journal of respiratory and critical care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00741013 (Imaging Biomarkers of Pulmonary Inflammation), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imaging Biomarkers of Pulmonary Inflammation
Who cites it
37 citing papers in PubMed, 56 citations in OpenAlex.
- COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome.European journal of nuclear medicine and molecular imaging · 2021Trial
- Positron Emission Tomography With 18F-Fluorodeoxyglucose in Patients With Sickle Cell Acute Chest Syndrome.Medicine · 2015Trial
- Imaging pulmonary inducible nitric oxide synthase expression with PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015Trial
- Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.International journal of molecular sciences · 2025Review
- Targeted imaging of pulmonary fibrosis by a cyclic peptide LyP-1.Scientific reports · 2025Article
- Development of lung cancer risk prediction models based on F-18 FDG PET images.Annals of nuclear medicine · 2023Article
- 2-deoxy-2-[Molecular imaging and biology · 2023Article
- Adjunctive Integrated Stress Response Inhibition Accelerates Tuberculosis Clearance in Mice.mBio · 2023Article
- Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The imaging quantification of multiple organs by dynamicInternational journal of medical sciences · 2022Article
- PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022Article
- Consensus Recommendations on the Use ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Quantification of regional murine ozone-induced lung inflammation using [Scientific reports · 2020Article
- Quantification and reliability of [EJNMMI research · 2020Article
- Use of autologousThorax · 2019Article
- Article
- Quantitative analysis of dynamicEJNMMI research · 2017Article
- Article
- Quantification of Lung PET Images: Challenges and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Imaging in acute respiratory distress syndrome.Intensive care medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
rationaleFew noninvasive biomarkers for pulmonary inflammation are currently available that can assess the lung-specific response to antiinflammatory treatments. Positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) is a promising new method that can be used to quantify pulmonary neutrophilic inflammation.
objectivesTo evaluate the ability of FDG-PET to measure the pulmonary antiinflammatory effects of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and recombinant human activated protein C (rhAPC) in a human model of experimentally-induced lung inflammation.
methodsEighteen healthy volunteers were randomized to receive placebo, lovastatin, or rhAPC before intrabronchial segmental endotoxin challenge. FDG-PET imaging was performed before and after endotoxin instillation. The rate of [(18)F]FDG uptake was calculated as the influx constant K(i) by Patlak graphical analysis. Bronchoalveolar lavage (BAL) was performed to determine leukocyte concentrations for correlation with the PET imaging results. MEASUREMENTS AND MAIN
resultsThere was a statistically significant decrease in K(i) in the lovastatin-treated group that was not seen in the placebo-treated group, suggesting attenuation of inflammation by lovastatin treatment despite a small decrease in BAL total leukocyte and neutrophil counts that was not statistically significant. No significant decrease in K(i) was observed in the rhAPC-treated group, correlating with a lack of change in BAL parameters and indicating no significant antiinflammatory effect with rhAPC.
conclusionsFDG-PET imaging is a sensitive method for quantifying the lung-specific response to antiinflammatory therapies and may serve as an attractive platform for assessing the efficacy of novel antiinflammatory therapies at early phases in the drug development process. Clinical trial registered with www.clinicaltrials.gov (NCT00741013).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.